Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer

The phase 3 KEYNOTE‐177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite‐instability‐high (MSI‐H)/mismatch‐repair‐deficient (dMMR) metastatic colorectal cancer (mCRC). Primary endpoints were progression‐free s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshino, Takayuki, Andre, Thierry, Kim, Tae Won, Yong, Wei Peng, Shiu, Kai‐Keen, Jensen, Benny Vittrup, Jensen, Lars Henrik, Punt, Cornelis J. A., Smith, Denis, Garcia‐Carbonero, Rocio, Alcaide‐Garcia, Julia, Gibbs, Peter, de la Fouchardiere, Christelle, Rivera, Fernando, Elez, Elena, Le, Dung T., Adachi, Noriaki, Fogelman, David, Marinello, Patricia, Diaz, Luis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986093/
https://www.ncbi.nlm.nih.gov/pubmed/36369901
http://dx.doi.org/10.1111/cas.15650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986093/
https://www.ncbi.nlm.nih.gov/pubmed/36369901
http://dx.doi.org/10.1111/cas.15650

Ejemplares similares